TCW Group’s NeoGenomics NEO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
– Sell
-233,162
Closed -$7.96M – 322
2021
Q4
$7.96M Sell
233,162
-33,150
-12% -$1.3M 0.07% 165
2021
Q3
$12.8M Buy
266,312
+121,946
+84% +$5.65M 0.03% 134
2021
Q2
$6.52M Sell
144,366
-32,459
-18% -$1.44M 0.06% 184
2021
Q1
$8.53M Sell
176,825
-37,375
-17% -$1.95M 0.08% 156
2020
Q4
$11.5M Sell
214,200
-57,893
-21% -$2.62M 0.1% 127
2020
Q3
$10M Sell
272,093
-52,972
-16% -$1.97M 0.11% 124
2020
Q2
$10.1M Sell
325,065
-51
-0% -$1.41K 0.12% 120
2020
Q1
$8.98M Buy
325,116
+164,502
+102% +$4.93M 0.12% 117
2019
Q4
$4.7M Buy
160,614
+148,297
+1,204% +$3.53M 0.05% 166
2019
Q3
$236K Buy
+12,317
New +$289K ﹤0.01% 289

Other funds holding NEO

TCW Group's NEO Position: Q1 2022 in Review

TCW Group sold out of NeoGenomics (NEO) in Q1 2022, closing a stake of 233,162 shares — an estimated $7.96M sold.

TCW Group first reported a position in NEO in Q3 2019 and held it in 10 quarters. The position peaked at $12.8M in Q3 2021. 279 funds tracked by Wall St. Rank hold NEO as of Q1 2022.

  • TCW Group reported no remaining NeoGenomics position as of Q1 2022 after selling out during the quarter.
  • TCW Group sold 233,162 NeoGenomics shares in Q1 2022, an estimated $7.96M.
  • TCW Group first reported a position in NeoGenomics in Q3 2019 and held it in 10 quarters.
  • TCW Group's NeoGenomics position peaked at $12.8M in Q3 2021.
  • 279 funds tracked by Wall St. Rank held NeoGenomics as of Q1 2022.

Based on TCW Group's 13F filing for Q1 2022, filed 19 Apr 2022.